Expression of MMP, HPSE, and FAP in Stroma Promoted Corneal Neovascularization Induced by Different Etiological Factors

REFERENCES

• Folkman J. Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6:273–286.
   PubMed Web of Science ®Google Scholar
• Pakneshan P, Birsner AE, Adini I, et al. Differential suppression of vascular permeability and corneal angiogenesis by nonsteroidal anti-inflammatory drugs. Invest Ophthalmol Vis Sci. 2008;49:3909–3913.
   PubMed Web of Science ®Google Scholar
• Gebhardt BM, Shi W. Experimental corneal allograft rejection. Immunol Res. 2002;25:1–26.
   PubMed Web of Science ®Google Scholar
• Elkin M, Miao HQ, Nagler A, et al. Halofuginone: A potent inhibitor of critical steps in angiogenesis progression. FASEB J. 2000;14:2477–2485.
   PubMed Web of Science ®Google Scholar
• Yoshida D, Noha M, Watanabe K, et al. Novel approach to analysis of in vitro tumor angiogenesis with a variable-pressure scanning electron microscope: Suppression by matrix metalloproteinase inhibitor SI-27. Brain Tumor Pathol. 2001;18:89–100.
   PubMedGoogle Scholar
• Kaliski A, Maggiorella L, Cengel KA, et al. Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion. Mol Cancer Ther. 2005;4:1717–1728.
   PubMed Web of Science ®Google Scholar
• Chang SH, Kanasaki K, Gocheva V, et al. VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation. Cancer Res. 2009;69:4537–4544.
   PubMed Web of Science ®Google Scholar
• van Hinsbergh VW, Koolwijk P. Endothelial sprouting and angiogenesis: Matrix metalloproteinases in the lead. Cardiovasc Res. 2008;78:203–212.
   PubMed Web of Science ®Google Scholar
• van Hinsbergh VW, Engelse MA, Quax PH. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol. 2006;26:716–728.
   PubMed Web of Science ®Google Scholar
• Staton CA, Stribbling SM, Tazzyman S, et al. Current methods for assaying angiogenesis in vitro and in vivo. Int J Exp Pathol. 2004;85:233–248.
   PubMed Web of Science ®Google Scholar
• Kwon YS, Hong HS, Kim JC, et al. Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo. Invest Ophthalmol Vis Sci. 2005;46:454–460.
   PubMed Web of Science ®Google Scholar
• Damms T, Ross JR, Duplessie MD, et al. Intracorneal bovine albumin: An immunologic model of corneal angiogenesis. Graefes Arch Clin Exp Ophthalmol. 1997;235:662–666.
   PubMed Web of Science ®Google Scholar
• Rogers MS, Birsner AE, D’Amato RJ. The mouse cornea micropocket angiogenesis assay. Nat Protoc. 2007;2:2545–2550.
   PubMed Web of Science ®Google Scholar
• Jia WD, Xu GL, Sun HC, et al. Effect of octreotide on angiogenesis induced by hepatocellular carcinoma in vivo. Hepatobiliary Pancreat Dis Int. 2003;2:404–409.
   PubMedGoogle Scholar
• Davis GE, Senger DR. Endothelial extracellular matrix: Biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res. 2005;97:1093–1107.
   PubMed Web of Science ®Google Scholar
• Milde F, Bergdorf M, Koumoutsakos P. A hybrid model for three-dimensional simulations of sprouting angiogenesis. Biophys J. 2008; 95:3146–3160.
   PubMed Web of Science ®Google Scholar
• Chang SH, Kanasaki K, Gocheva V, et al. VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation. Cancer Res. 2009;69:4537–4544.
   PubMed Web of Science ®Google Scholar
• Kalluri R. Basement membranes: Structure, assembly and role in tumour angiogenesis. Nat Rev Cancer. 2003;3:422–433.
   PubMed Web of Science ®Google Scholar
• Zucker S, Mirza H, Conner CE, et al. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer. 1998;75:780–786.
   PubMed Web of Science ®Google Scholar
• Bauer AL, Jackson TL, Jiang Y. Topography of extracellular matrix mediates vascular morphogenesis and migration speeds in angiogenesis. PLoS Comput Biol. 2009;5:e1000445.
   PubMed Web of Science ®Google Scholar
• Karagiannis ED, Popel AS. Distinct modes of collagen type i proteolysis by matrix metalloproteinase (MMP) 2 and membrane type i MMP during the migration of a tip endothelial cell: Insights from a computational model. J Theor Biol. 2006;238:124–145.
   PubMed Web of Science ®Google Scholar
• Simizu S, Ishida K, Osada H. Heparanase as a molecular target of cancer chemotherapy. Cancer Sci. 2004;95:553–558.
   PubMed Web of Science ®Google Scholar
• Dreyfuss JL, Regatieri CV, Jarrouge TR, et al. Heparan sulfate proteoglycans: Structure, protein interactions and cell signaling. An Acad Bras Cienc. 2009;81:409–429.
   PubMed Web of Science ®Google Scholar
• Sanderson RD, Yang Y, Kelly T, et al. Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: Growth regulation and the prospect of new cancer therapies. J Cell Biochem. 2005;96:897–905.
   PubMed Web of Science ®Google Scholar
• Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol. 2006;38:2018–2039.
   PubMed Web of Science ®Google Scholar
• Parish CR, Freeman C, Hulett MD. Heparanase: A key enzyme involved in cell invasion. Biochim Biophys Acta. 2001;1471:M99–M108.
   PubMed Web of Science ®Google Scholar
• Vlodavsky I, Goldshmidt O, Zcharia E, et al. Molecular properties and involvement of heparanase in cancer progression and normal development. Biochimie. 2001;83:831–839.
   PubMed Web of Science ®Google Scholar
• Vlodavsky I, Ilan N, Naggi A, et al. Heparanase: Structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des. 2007;13:2057–2073.
   PubMed Web of Science ®Google Scholar
• Miao HQ, Liu H, Navarro E, et al. Development of heparanase inhibitors for anti-cancer therapy. Curr Med Chem. 2006;13:2101–2111.
   PubMed Web of Science ®Google Scholar
• Puré E. The road to integrative cancer therapies: Emergence of a tumor-associated fibroblast protease as a potential therapeutic target in cancer. Expert Opin Ther Targets. 2009;13:967–973.
   PubMed Web of Science ®Google Scholar
• Fassnacht M, Lee J, Milazzo C, et al. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: Implication for cancer immunotherapy. Clin Cancer Res. 2005;11:5566–5571.
   PubMed Web of Science ®Google Scholar
• Cheng JD, Weiner LM. Tumors and their microenvironments: Tilling the soil. Clin Cancer Res. 2003;9:1590–1595.
   PubMed Web of Science ®Google Scholar
• Bhati R, Patterson C, Livasy CA, et al. Molecular characterization of human breast tumor vascular cells. Am J Pathol. 2008;172:1381–1390.
   PubMed Web of Science ®Google Scholar
• Wang T, Shi W. Expression of fibroblast activation proteins in corneal stromal neovascularization. Curr Eye Res. 2009;34:112–117.
   PubMed Web of Science ®Google Scholar